Miguel F. D. S. G.
- Country
- Spain
- Department
- Unidad Central de Ensayos Clínicos
Research Overview
- Evaluation of Repotrectinib and CYP450 Probe Cocktail in TKI-Pretreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- Tarlatamab plus Durvalumab versus Durvalumab Alone in Patients with Extensive-Stage Small Cell Lung Cancer Following Platinum-Etoposide Therapy
Data & Insights
Has run more than one trial at 286 of 494 partner sites.
Specializations
Lung Cancer Expertise
Specializes in advanced therapeutic approaches for non-small cell lung cancer (NSCLC), with particular focus on both early-stage resectable and metastatic disease states.
- Treatment-naïve NSCLC
- Squamous and non-squamous subtypes
- RET fusion-positive NSCLC
Investigates novel combination therapies involving immunotherapy and targeted treatments for lung cancer patients.
Immunotherapy Research
Leads investigations into innovative immunotherapy combinations and novel treatment approaches for solid tumors.
- PD-1/PD-L1 inhibitor therapies
- Checkpoint inhibitor combinations
- Cancer vaccines
Focuses on developing personalized immunotherapy strategies for various cancer types.
Precision Medicine
Conducts research on targeted therapies for specific genetic mutations and molecular subtypes of cancer.
- KRAS G12C mutations
- EGFR mutations
- ROS1 and ALK rearrangements
Explores biomarker-driven treatment approaches in advanced solid tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.